VIDEO: Faricimab shows greater reduction in hard exudates in patients with DME
SEATTLE — In this Healio Video Perspective from the ARVO meeting, Roger A. Goldberg, MD, MBA, discusses an analysis examining the resolution of hard exudates in patients with diabetic macular edema treated with faricimab vs. aflibercept.
A post hoc analysis of data from the phase 3 YOSEMITE and RHINE trials showed “about a 10% absolute reduction in the proportion of patients who have hard exudates at year 1 and year 2 when treated with faricimab,” he said.
Collapse
Goldberg RA, et al. Greater reduction in hard exudates with faricimab vs aflibercept in patients with DME: Biomarker results from the phase 3 YOSEMITE/RHINE trials. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Read more about